ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury

Contributed by: GlobeNewswire

Tags

FDA De Novo Clearance

More Like This

ONWARD Medical Announces First Commercial Sales of ARC-EX System

GlobeNewswire associated0

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

GlobeNewswire associated0

Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy

ONWARD® Medical Announces Publication Highlighting Evidence-based Programming for ARC-EX® Therapy

ONWARD® Medical Reaffirms 2024 Strategic Priorities and Releases Unaudited Q2 Financial Highlights

ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date